the amebae in plant B’s water suggests the importance of enhanced chlorine pumping at distribution points beyond water treatment plants for maintain residual chlorine in Karachi’s domestic water supply.

Because water supply can be intermittent, underground and overhead storage tanks are essential for Karachi homes. To ensure continuous domestic supply, water is stored in overhead tanks and pumped from tanks into homes as needed. Water storage in tanks perhaps facilitated propagation of *N. fowleri* amebae in domestic and mosque water. During the summer, ambient temperatures reach 44°C, leading to increased water temperatures in overhead tanks. We found water temperatures up to 34°C, which may facilitate excystation of *N. fowleri* amebae to infective forms. Slime, dirt, and high ambient temperatures likely explain *N. fowleri* multiplication in storage tanks, the possible source of infection for this patient in Karachi.

Presence of *N. fowleri* amebae in mosque water is alarming. Ablution (Wudhu) is a ritual performed by Muslims before offering prayers and involves thorough cleaning of mouth, ears, face, arms, feet, and nasal passages, the latter by inhaling water forcefully up the nostrils. Performing this activity with contaminated water could be a communal source for potential outbreaks.

Karachi water supply authorities have initiated chlorine enhancement at various sites beyond plant B, and our findings support the need for this enhancement. We recommend that the government implement measures to maintain appropriate chlorine levels in the domestic water supply and at recreational sites and to develop effective ameba-monitoring programs. The public should use boiled or filtered water for nasal cleansing, regularly clean storage tanks, and add supplemental chlorine to water in homes, especially during the summer.

Acknowledgments
We thank the Karachi Water and Sewerage Board and residents of Karachi for providing water samples.

References

Unmet Needs for a Rapid Diagnosis of Chikungunya Virus Infection

Elisa Burdino, Guido Calleri, Pietro Caramello, Valeria Ghisetti

Author affiliation: Amedeo di Savoia Hospital, Torino, Italy

DOI: http://dx.doi.org/10.3201/eid2210.151784

To the Editor: Chikungunya virus (CHIKV) has become a global health problem. Clinical manifestations are not specific and are difficult to differentiate from those of similar viral diseases (e.g., dengue and Zika virus disease). Diagnostic laboratories must be prepared to meet the changing epidemiology of viral diseases. CHIKV infection is currently identified by viral genome detection, using reverse transcription PCR (RT-PCR), viral culture, and serologic testing for IgG and IgM by indirect immunofluorescence (IFA) or ELISA. RT-PCR is most sensitive during the early phase of CHIKV infection (within 5–7 days of symptom onset), but its use is limited by the short viremic phase of the disease. After the acute phase, serologic testing for IgG and IgM is a more accurate indicator of disease.
Molecular and serologic tests are complementary, reliable, and sensitive methods, but they require special equipment and a medium-to-high level of technical skill that may not be available in many laboratories, especially those in rural areas, where outbreaks usually occur.

Accurate and rapid detection of CHIKV infection by reliable point-of-care (POC) assays has been recommended to facilitate outbreak control. To meet this need, rapid CHIKV IgM POC tests are now available, but little information exists regarding their performance. The sensitivity of these tests evaluated in settings with a high prevalence of CHIKV infection is poor (range 1.9%–50.8%) compared with that for reference assays, especially in the acute phase of disease (1–5). In low-prevalence settings, CHIKV infection generally occurs as imported cases in travelers returning from disease-endemic countries. Diagnosis of such cases requires discrimination between CHIKV, dengue, Zika, and other febrile diseases in the differential diagnosis; this discrimination could be facilitated by the use of a reliable POC assay. The recent Zika virus disease outbreak in South America also highlights the worldwide need for rapid reliable POC tests.

From June 2014 through November 2015, eight patients who had returned to Italy from the Caribbean and Latin America were referred to the regional Center for Infectious Diseases, Amedeo di Savoia Hospital, in Turin for travel-associated CHIKV infection. These cases were the first in the region after 3 years without imported cases. We used IFA (Euroimmun AG, Lubeck, Germany) and realtime RT-PCR (TIB MOLBIOL GmbH, Berlin, Germany) for CHIKV diagnosis. In addition, we evaluated the OnSite Chikungunya IgM Combo Rapid Test CE (CTK Biotech, San Diego, CA, USA) for CHIKV infection.

The rapid test identified IgM in only 3 of 8 patients (sensitivity 37.5%). All patients were negative for viral RNA, probably due to the time elapsed between symptom onset and serum sample collection, as confirmed by the presence of CHIKV IgG in most patients. No false-positive or invalid results were recorded with the rapid test on 30 CHIKV-negative serum samples (specificity 100%; positive and negative predictive values 37.5% and 100%, respectively).

Rapid and appropriate diagnostic tools are needed to slow or stop the worldwide spread of CHIKV. Rapid POC tests are highly cost-effective because they are easy to perform and can be disseminated to many laboratories for differentiating between diseases that are similar. Moreover, their results can easily be evaluated and shared within networks of reference laboratories.

However, our findings, in agreement with those of others, show that current rapid CHIKV tests perform poorly and need major improvement (Table) (1–5). This poor performance might have several explanations. For example, CHIKV patients do not often seek medical care in the early course of the disease. Most patients in our study were no longer in the acute phase of illness: the diagnosis was made a mean of 16.8 (range 7–30) days after fever onset, and when tested, all patients were viral RNA–negative by real-time RT-PCR. POC reactivity generally increases in patients with illness duration of >1 week (1–5), but this

### Table. Reported sensitivity and specificity of rapid point-of-care tests for detecting chikungunya virus, 2008–2015*

<table>
<thead>
<tr>
<th>Reference and test(s)</th>
<th>Time from symptom onset to testing, d</th>
<th>Sensitivity, %†</th>
<th>Specificity, %‡</th>
<th>Test reference standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) OnSite Chikungunya IgM Rapid Test</td>
<td>1 to &gt;21</td>
<td>20.5</td>
<td>100</td>
<td>Capture ELISA IgM (in house) with Asian lineage virus; rRT-PCR</td>
</tr>
<tr>
<td>SD BIOLINE Chikungunya IgM test</td>
<td>1 to &gt;21</td>
<td>50.8</td>
<td>89.2</td>
<td>Capture ELISA IgM (in house) with Asian lineage virus; rRT-PCR</td>
</tr>
<tr>
<td>(2) SD BIOLINE Chikungunya IgM test</td>
<td>&lt;7; 8 to &gt;14§</td>
<td>22; 83</td>
<td>88; 71</td>
<td>ELISA IgM; rRT-PCR</td>
</tr>
<tr>
<td>(3) OnSite Chikungunya IgM Rapid Test</td>
<td>3.75 to &gt;7</td>
<td>12.1</td>
<td>100</td>
<td>IgM IFA; capture ELISA IgM (in house); rRT-PCR</td>
</tr>
<tr>
<td>(4) SD BIOLINE Chikungunya IgM test</td>
<td>3–8</td>
<td>1.9–3.9</td>
<td>92.5–95.0</td>
<td>Capture ELISA IgM; rRT-PCR</td>
</tr>
<tr>
<td>(5) OnSite Chikungunya IgM Combo Rapid Test CE</td>
<td>NA</td>
<td>20</td>
<td>93</td>
<td>Capture ELISA IgM/IgG (in house); plaque reduction neutralization test</td>
</tr>
<tr>
<td>SD BIOLINE Chikungunya IgM test</td>
<td>NA</td>
<td>30</td>
<td>73</td>
<td>Capture ELISA IgM/IgG (in house); plaque reduction neutralization test</td>
</tr>
</tbody>
</table>

This study
OnSite Chikungunya IgM Combo Rapid Test CE 7 to 30 37.5 100 IFA IgM/IgG (commercial); rRT-PCR

*IFA, indirect immunofluorescence assay; NA, not applicable; rRT-PCR, real-time reverse transcription PCR.

†Manufacturers: CTK Biotech, San Diego, CA, USA (OnSite Chikungunya IgM Combo Rapid Test CE and OnSite Chikungunya IgM Rapid Test); Standard Diagnostics, Inc., Seoul, South Korea (SD BIOLINE Chikungunya IgM test).

‡Values are those reported in the original publications.

§Testing was done at 2 different time points after symptom onset.
was not the case in our study. Genetic differences in circulating CHIKV lineages could also explain poor testing performance. Furthermore, the OnSite Chikungunya IgM Combo CE POC test uses a recombinant antigen covering the 226 residues of the E1 gene from CHIKV variant A226; recent studies on CHIKV protein characterization showed that more sensitive serologic assays can be obtained using specific early-phase E2 glycoprotein as antigens (3).

The successful use of rapid immunochromatography-based assays with monoclonal antibodies to detect viral diseases (e.g., dengue) has encouraged the development of rapid immunoassays for CHIKV antigens, and preliminary results for these assays seem promising (6). External quality assessment programs for POC tests and quality controls consisting of standardized positive serum could also be helpful for improving the performance of diagnostic tests.

In conclusion, returning travelers are sentinels of the rapidly changing epidemiology of CHIKV; thus, they require a prompt diagnosis and careful surveillance for their possible role in subsequent autochthonous disease transmission. Implementation of user-friendly, rapid, and easily deliverable POC tests for a prompt and accurate laboratory diagnosis is therefore needed to improve patient management and disease control measures.

Acknowledgments
We thank the Carlo De Negri Foundation for their support (N.650/007B/2011) and staff of the Unit of Serology and Molecular Biology, Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, for their excellent technical assistance.

References

Address for correspondence: Elisa Burdino, Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Corso Svizzera 164, I-10149 Torino, Italy: email: elisa.burdino@libero.it

Novel Single-Stranded DNA Circular Viruses in Pericardial Fluid of Patient with Recurrent Pericarditis

Sébastien Halary, Raja Duraisamy, Laura Fancello, Sonia Monteil-Bouchard, Priscilla Jardot, Philippe Biagini, Frédérique Gouriet, Didier Raoult, Christelle Desnues

Author affiliations: Institut Hospitalo-Universitaire Méditerranée-Infection, Marseille, France (S. Halary, R. Duraisamy, L. Fancello, S. Monteil-Bouchard, P. Jardot, P. Biagini, F. Gouriet, D. Raoult, C. Desnues); Aix-Marseille Université, Marseille (S. Halary, R. Duraisamy, L. Fancello, S. Monteil-Bouchard, P. Jardot, P. Biagini, F. Gouriet, D. Raoult, C. Desnues); Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Marseille (S. Halary, R. Duraisamy, L. Fancello, S. Monteil-Bouchard, P. Jardot, F. Gouriet, D. Raoult, C. Desnues); KU Leuven, Leuven, Belgium (L. Fancello); Unité Mixte de Recherche, Marseille (P. Biagini); Etablissement Français du Sang, Marseille (P. Biagini); Centre National de la Recherche Scientifique, Marseille (P. Biagini, C. Desnues)

DOI: http://dx.doi.org/10.3201/eid2210.160052

To the Editor: Circular replication initiation protein (Rep)–encoding single-stranded DNA (ssDNA) (CRESS-DNA) genomes are found in diverse group II virus families, which all possess a conserved Rep-encoding gene and a nonenvelopedicosahedral capsid, except geminiviruses, which have twinned particles (1). Geminicircular-larvirus (GcV) were initially discovered in fungi, but a growing number of new species has been characterized by metagenomics in air, sewage, insects, and feces from a broad range of vertebrates (1–5). GcVs have also been found in the brain and serum of humans with multiple sclerosis; in the cerebrospinal fluid of a patient with encephalitis; and in several blood samples, including those from an HIV-positive blood donor (6–8). We report the presence of 2 divergent GcVs and a novel CRESS-DNA virus (CV) in 2 pericardial fluid samples from a patient with idiopathic recurrent pericarditis.